Credit Suisse Upgrades St. Jude Medical (STJ) to Outperform

Go back to Credit Suisse Upgrades St. Jude Medical (STJ) to Outperform

St. Jude Medical (STJ) PT Lifted to $82 at Wedbush Following Strong Q1

April 23, 2015 7:55 AM EDT

Wedbush analyst Tao Levy reiterated an Outperform rating and raised his price target on St. Jude Medical (NYSE: STJ) to $82.00 (from $77.00) following "impressive" Q1 results.

Levy commented, "Impressive 1Q results for St. Jude Medical, driven by CardioMEMS, Atrial Fibrillation, and Neuromodulation; bodes well... More

St. Jude Medical (STJ) Price Target Lifted to $86 at Needham & Company

April 22, 2015 11:28 AM EDT

Needham & Company analyst Mike Matson reiterated a Strong Buy rating and raised his price target on St. Jude Medical (NYSE: STJ) to $86.00 (from $83.00)

Matson commented, "STJ's 1Q15 revenue and EPS beat consensus. Management raised its 2015 constant currency revenue guidance given better than expected 1Q15 growth and... More

St. Jude Medical (STJ) Tops Q1 EPS by 2c; Guides Q1 EPS to Strong-Side of Views

April 22, 2015 7:16 AM EDT

St. Jude Medical (NYSE: STJ) reported Q1 EPS of $0.93, $0.02 better than the analyst estimate of $0.91. Revenue for the quarter came in at $1.35 billion versus the consensus estimate of $1.32 billion.

Outlook:

St. Jude Medical sees Q2 2015 EPS of $0.99 - $1.01, versus... More